A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
NCT ID: NCT06732895
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
24 participants
INTERVENTIONAL
2024-12-10
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo for Navepegritide
Once weekly double-blinded treatment with SC injection of 100 µg/kg of placebo for navepegritide for 52 weeks
Placebo for navepegritide
Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Navepegritide
Once weekly double-blinded treatment with SC injection of 100 µg/kg of navepegritide for 52 weeks
Navepegritide
Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Navepegritide
Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
Placebo for navepegritide
Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, between 12 (inclusive) and 18 years of age at the time of randomization
* Clinical diagnosis of ACH with documented genetic confirmation available. Documentation of historic test results are acceptable for proof of diagnosis.
* Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of IMP and to follow the protocol.
* At least one historical standing height measurement available from medical records. The measurement must have been collected between 6 months to 15 months prior to the time of screening.
Exclusion Criteria
* Decreased growth velocity (AGV less than 1.5 cm/year based on measurement over a period of at least 6 months) or radiological evidence of growth plate closure.
* Known or suspected hypersensitivity to the IMP or related products (trehalose, tris\[hydroxymethyl\]aminomethane, succinate, and mPEG).
* Have a growth disorder or medical condition other than ACH that results in short stature, or abnormal growth such as SADDAN, hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudo-ACH, inflammatory bowel disease, celiac disease, hypothyroidism, hyperthyroidism, or diabetes mellitus.
* Severe mutation in the FGFR3 gene, e.g. two variants on the same allele or severe ACH with developmental delay and acanthosis nigricans, are not eligible for trial participation.
* Have received any dose of prescription medications and/or IMP (placebo treatment only is allowed, if documented) or surgical intervention intended to affect stature, growth, or body proportionality at any time.
* Requires, or anticipated to require, chronic (more than 4 weeks) or repeated treatment (more than twice/year and less than 3 weeks/year) with systemic corticosteroids during participation in the trial. Chronic use of high dose inhaled corticosteroids is not allowed.
* Known history of presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
* Known history of any bone-related surgery affecting growth potential of long bones, such as:
* Orthopedic reconstructive surgery for bone lengthening (e.g., procedures for leg bowing such as 8-plate are not exclusionary).
* Ventriculoperitoneal (VP) shunt and laminectomy with full recovery are allowed with minimum of 6 months of bone healing.
* Bone fracture within 6 months prior to screening (within 2 months for fracture of digits and buckle fractures).
* Clinically significant findings at Screening, such as:
* Expected to require surgical intervention during participation in the trial that may significantly affect trial parameters (confounding of safety events) or would prevent the participant from performing trial procedures. Common surgeries, such as insertion of grommets, adenoidectomy, tonsillectomy, or myringotomy tube placement, are permitted.
* Severe untreated sleep apnea or newly initiated sleep apnea treatment (e.g., Continuous Positive Airway Pressure \[CPAP\] in the previous 2 months prior to Screening.
* MS disease, such as Salter-Harris fractures or clinical and/or radiographic evidence of severe hip pathology
* Otherwise, are considered by the Investigator to be unfit to receive trial treatment or undergo trial related procedures.
* Have a clinically significant finding or arrhythmia as determined by the investigator in consultation with the medical monitor that indicates abnormal cardiac function or conduction that includes, but is not exclusive to:
* Repaired or unrepaired coarctation.
* Moderate or greater complexity congenital heart disease including tetralogy of Fallot, Atrioventricular septal defects, truncus arteriosus, total anomalous pulmonary venous return, double outlet right ventricle, or single ventricle heart disease.
* QT corrected using Fridericia's correction (QTcF) ≥ 450 msec at Screening.
* Known history or presence of condition that impacts hemodynamic stability (such as autonomic dysfunction and orthostatic intolerance).
* Known history or presence of the following:
* Chronic anemia (iron deficiency anemia that is resolved or adequately treated in the Investigator's opinion is allowed).
* Chronic renal insufficiency defined as estimated glomerular filtration rate (eGFR) according to the revised bedside Schwartz equation less than 60 mL/min/1.73 m2 for more than 3 months.
* Chronic or recurrent illness that can affect hydration or volume status, including conditions associated with decreased nutritional intake or increased volume loss.
* Known history or presence of malignant disease.
* Participant with serum 25-hydroxy-vitamin D (25OHD) levels of less than 30 nmol/L (less than 12 ng/mL) at Screening Visit will be excluded. Participants with 25OHD levels between 30-50 nmol/L (12-20 ng/mL) can be randomized provided treatment with Vitamin D supplementation is initiated according to local standards.
* Any disease or condition that, in the opinion of the Investigator, may make the participant unlikely to fully complete the trial, may confound interpretation of trial results, or may present undue risk from receiving trial treatment. This could include family situations, complications or manifestations, or medications that might impact safety or be considered confounding.
* Sexually active male and female participants and female partners of male participants of childbearing potential not using a highly effective form of contraceptive for the entire trial period and for 90 days after last dose of trial treatment.
* Female participants who are pregnant, lactating or breastfeeding.
12 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ascendis Pharma A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director, MD
Role: STUDY_DIRECTOR
Ascendis Pharma A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ascendis Investigational Site
Montreal, , Canada
Ascendis Investigational Site
Copenhagen, , Denmark
Ascendis Investigational Site
Paris, , France
Ascendis Investigational Site
Dublin, , Ireland
Ascendis Investigational Site
Norwich, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-514208-15-00
Identifier Type: CTIS
Identifier Source: secondary_id
ASND0045
Identifier Type: -
Identifier Source: org_study_id